HIV vaccine hopes dashed by trial results

Hopes have been dashed an experimental vaccine could protect individuals versus HIV, the infection that triggers Aids.

The National Institutes of Health has stopped its HVTN 702 trial, of more than 5,000 individuals in South Africa, as it discovered the jab did not avoid HIV.

Professionals revealed “deep disappointment” but added the look for a preventive HIV vaccine need to continue.

Such vaccines do not include HIV and for that reason do not posture any danger of offering HIV to an individual.

What was the vaccine?

The jab was a new variation of the very first HIV-vaccine candidate revealed to offer some protection against the infection – in the RV144 scientific trial, in Thailand

There are several stress of HIV and the vaccine had been adjusted to the subtype most common is South Africa, which has one of the highest HIV rates in the